GSK (GSK) notes that the U.S. Administration has initiated an investigation under Section 232 of the Trade Expansion Act to determine the effects on national security of imports of pharmaceutical products. The company is well positioned to respond to the potential financial impact of sector-specific tariffs, should they be implemented, with mitigation options identified in the supply chain and productivity initiatives. The company will continue to monitor and review developments related to this situation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GSK:
- GlaxoSmithKline Faces Sell Rating Amid EPS Decline and Pipeline Concerns
- GSK price target lowered to 1,170 GBp from 1,190 GBp at HSBC
- GlaxoSmithKline (GSK) Q1 Earnings Cheat Sheet
- GSK Announces Share Buyback on April 24, 2025
- Trump looking at cutting drug prices to international levels, Reuters says